Kidder Stephen W raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 14.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 20,547 shares of the biopharmaceutical company’s stock after acquiring an additional 2,665 shares during the period. Kidder Stephen W’s holdings in Gilead Sciences were worth $1,396,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Bank of New York Mellon Corp grew its stake in shares of Gilead Sciences by 9.8% during the 1st quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock valued at $2,076,368,000 after buying an additional 2,727,063 shares during the period. Parnassus Investments CA grew its stake in shares of Gilead Sciences by 37.4% during the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after buying an additional 4,556,901 shares during the period. APG Asset Management N.V. grew its stake in shares of Gilead Sciences by 16.7% during the 1st quarter. APG Asset Management N.V. now owns 5,923,426 shares of the biopharmaceutical company’s stock valued at $402,319,000 after buying an additional 849,741 shares during the period. Swiss National Bank grew its stake in shares of Gilead Sciences by 26.9% during the 1st quarter. Swiss National Bank now owns 4,668,124 shares of the biopharmaceutical company’s stock valued at $317,059,000 after buying an additional 989,400 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its stake in shares of Gilead Sciences by 3.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 4,404,045 shares of the biopharmaceutical company’s stock valued at $299,123,000 after buying an additional 150,318 shares during the period. Institutional investors own 74.05% of the company’s stock.
Several analysts have recently issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of Gilead Sciences in a research note on Thursday. They set an “outperform” rating and a $94.00 price objective for the company. ValuEngine cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. TheStreet raised shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Zacks Investment Research cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday, September 11th. Finally, Berenberg Bank reaffirmed a “buy” rating and set a $96.00 price target (up from $86.00) on shares of Gilead Sciences in a research report on Wednesday, September 6th. Eleven investment analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $83.79.
WARNING: This news story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://ledgergazette.com/2017/09/16/gilead-sciences-inc-gild-shares-bought-by-kidder-stephen-w.html.
In related news, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the completion of the transaction, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at approximately $7,318,327.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the transaction, the insider now directly owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The disclosure for this sale can be found here. Insiders have sold a total of 466,819 shares of company stock valued at $36,740,240 over the last three months. 1.30% of the stock is currently owned by insiders.
Gilead Sciences, Inc. (GILD) traded up 0.09% on Friday, reaching $82.36. 12,401,948 shares of the company’s stock traded hands. The firm’s 50-day moving average is $77.16 and its 200 day moving average is $70.20. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The stock has a market capitalization of $107.56 billion, a PE ratio of 8.95 and a beta of 1.19.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. During the same period last year, the firm earned $3.08 EPS. The firm’s revenue for the quarter was down 8.2% compared to the same quarter last year. Analysts forecast that Gilead Sciences, Inc. will post $8.75 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.53%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.